On Monday, Moderna announced the success of its preliminary analysis. The Biotechnology firm’s coronavirus vaccine is nearly 95% effective. Thankfully the 2.5 billion the U.S Government invested in the company was a smart move. Moderna’s COVID-19 vaccine has proven to prevent illness, including serve cases.
Moderna will be joining its competitor Pfizer and BioNTech as one of the vaccines that may be released early next month.
“It’s extremely good news. If you look at the data, the numbers speak for themselves,” said Anthony S. Fauci, director of the National Institute of Allergy and Infectious Diseases.
The clinical trial facilitated by Modern and the Fauci Institute consists of 30,000 people; 50% of test studies received a placebo, and 50% received the vaccine. Physicians studied 95 cases of COVID-19 in the trail. 90 of the test studies received the placebo. 11 of those cases were reported to be severe.
According to Fauci, impressive data was collected on severe cases. Morena’s vaccine has proven that it can prevent any case of COVID-19. The National Institutes of Health analyzed the results received.
“In this pandemic, what has been awful from a public health standpoint, an economic standpoint, is the worry people have to get so sick they have to go to the hospital. They have to get to the ICU and have a high risk of dying. If a vaccine could prevent 95 percent of people to not get disease, but to not get severe disease, that would be a game-changer: the impact on hospitals, the impact on people’s psyche and the impact on deaths.” Stéphane Bancel, chief executive of Moderna said.
Moderna will complete their 151 case study before applying for emergency-use authorization. The trail is expected to reach its endpoint within the next 7-10 days. At this rate, the company should be able to submit all data before Thanksgiving. If so, The vaccine will be made available to high-risk individuals by late December.
The Biotechnology firm is extremely dedicated to creating an effective vaccine. In fact, they invested $2 billion themselves. In total, the company has spent $4.5 billion on research and development.
The Food and Drug Administration will be responsible for review and approval. Moderna plans to produce 20 million doses by the end of the year. Two does of the vaccine will be needed. Side effects are moderate and include pain at the injection site, fatigue, headache, and muscle pain. They also plan to produce 1 billion doses next year.